Search for a cell therapy manufacturing partner and you will find rankings. Top ten lists, market landscape reports, capability matrices where every provider ticks every box. They are useful for discovering that a company exists and close to useless for deciding whether it should make your product, because the attributes that actually determine that outcome are not the ones that fit in a comparison table.
The letter people skip
CDMO is the familiar term: contract development and manufacturing. CTDMO inserts testing, and the insertion is not decorative. It signals that analytical testing sits inside the organization rather than being subcontracted alongside it.
That matters because testing is where cell therapy programs stall. A manufacturing slot is worth little if release testing is queued behind someone else’s schedule, and an analytical method that needs developing is a bottleneck wherever it sits. Whether testing is internal changes who controls that timeline.
Where the starting material comes from
This is the question most capability comparisons omit entirely, and it determines more than most of the ones they include. A manufacturing partner who sources starting material from third parties has a supply chain with a seam in it, and seams are where continuity fails.
The relevant questions are whether collection is owned, whether donors can be characterized before selection rather than after, and whether the same donors can be returned to across the life of a program. A partner who collects, characterises and manufactures within one operation can hold the input constant while the process changes. A partner assembling those functions from vendors cannot promise that, however capable each vendor is.
Scale, and the scale you actually need
| Advertised | Worth asking instead |
|---|---|
| Total cleanroom footprint | How many suites are appropriate to my process, and when are they free |
| Number of programs supported | How many resemble mine in modality and scale |
| Commercial-scale capability | What happens to my slot if a larger program needs it |
| Full-service capability | Which parts are performed here and which are placed elsewhere |
| Regulatory support | What documentation do I receive, and in what form |
Small programs at very large providers are a well-known failure pattern. The capability is genuine and the attention is allocated elsewhere, which is a different problem from incapability and is harder to detect during selection.
Related product
Leukopak formats. Single-donor starting material, fresh or cryopreserved, with full donor documentation.
Geography, for the reason that actually matters
Location is usually discussed in terms of travel and time zones. The consequential version is proximity between collection, processing and manufacturing, because material degrades in transit and cell state is set long before manufacturing begins.
A bi-coastal footprint is worth something specific: clinical sites on either coast can reach a processing operation without a cross-country journey. OrganaBio operates from Miami with processing in Irvine and Hayward and, following the Excellos acquisition, San Diego, with ISO 7 cGMP cleanroom suites in Miami and San Diego.
The continuity question, again
Every program that succeeds eventually changes something: a process step, a scale, a grade. Each change asks whether the product is still the product, and each is far cheaper to answer when the starting material has not moved underneath it.
Sequencing a selection
Establish where starting material originates and whether it is owned. Establish whether testing is internal. Establish what happens to your slot when a larger program arrives. Establish what documentation you receive and whether you can reference it in your own filing. Then, and only then, compare the capability matrices, which by that point will mostly agree with each other.
OrganaBio operates as a CTDMO with collection through its own apheresis subsidiary, characterization at donor program level including high-resolution NGS HLA typing across six genes and KIR genotyping, and research and cGMP formats drawn from the same donor pool. Material formats are on the leukopak hub, and the grade transition is covered in moving from RUO to cGMP.
Frequently asked questions
What is the difference between a CDMO and a CTDMO?
CDMO covers contract development and manufacturing. CTDMO inserts testing, signalling that analytical testing sits inside the organization rather than being subcontracted. That matters because release testing and method development are common bottlenecks, and internal testing changes who controls that timeline.
What should I ask a manufacturing partner about starting material?
Whether collection is owned or sourced from third parties, whether donors are characterized before selection rather than after, and whether the same donors can be returned to across the life of the program. A supply chain with a seam in it is where continuity fails.
Why do small programs struggle at large manufacturing providers?
The capability is genuine but attention is allocated to larger programs. It is a different problem from incapability and considerably harder to detect during selection, which is why asking what happens to your slot when a bigger program arrives is worth more than a capability matrix.
Does the geography of a manufacturing partner matter?
Yes, though not mainly for travel. What matters is proximity between collection, processing and manufacturing, because material changes in transit and cell state is established long before manufacturing begins.
What is the most useful question to ask in a capability meeting?
Whether, if your process changes in eighteen months, you can still obtain material from the same donors under the same quality system to run the comparison. Most other capabilities are easier to replace than a yes to that.
How should I sequence a CTDMO selection?
Establish where starting material originates and whether it is owned, whether testing is internal, what happens to your slot when a larger program arrives, and what documentation you receive and can reference in your own filing. Compare capability matrices afterwards, when they will mostly agree.
Why is internal analytical testing significant?
Because a manufacturing slot is worth little if release testing is queued behind another organization’s schedule, and analytical methods that need developing are a bottleneck wherever they sit. Keeping testing internal puts that timeline under one roof.
Talk to OrganaBio
Working through this on a live program?
The scientific team works through sourcing and specification questions with cell therapy and research groups directly, including donor characterization, format selection and documentation scope.
